Showing results (41-50 of 63) with videos related to
Sort By:
Pageof 7
The Oncologist|December 15, 2015
High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast CancerTakahiro Kogawa, Tamer M Fouad, Diane D Liu, et al.Breast Cancer Research and Treatment|June 20, 2018
Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypesTakahiro Kogawa, Takeo Fujii, Tamer M Fouad, et al.European Journal of Cancer (Oxford, England : 1990)|December 13, 2017
Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancerTakeo Fujii, Naoko Matsuda, Miho Kono, et al.Plos One|March 28, 2020
EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapyFanny Le Du, Takeo Fujii, Kumiko Kida, et al.Journal of Cancer Survivorship : Research and Practice|March 13, 2025
Healthcare provider perspectives on a clinical decision tool to support individualized exercise prescriptions and discussions for breast cancer survivorsJinani Jayasekera, Oliver W A Wilson, Kaitlyn M Wojcik, et al.British Journal of Cancer|January 13, 2017
Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapyTakeo Fujii, Takahiro Kogawa, Jimin Wu, et al.Nature|July 16, 2025
Neutrophils drive vascular occlusion, tumour necrosis and metastasisJose M Adrover, Xiao Han, Lijuan Sun, et al.Cancer Medicine|December 8, 2025
A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA MutationTakeo Fujii, Ashley Cimino-Mathews, Stanley Lipkowitz, et al.The Oncologist|February 1, 2020
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without TrastuzumabTakahiro Kogawa, Takeo Fujii, Jimin Wu, et al.Cell Death & Disease|April 25, 2025
Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancerKei Kudo, Yoshimi Endo Greer, Daniel R Crooks, et al.Pageof 7